Navigation Links
Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test
Date:3/17/2011

y adopted for guiding treatment decisions in early-stage breast cancer and incorporated in published guidelines of leading cancer organizations.  Oncotype DX is available for use worldwide and, as of December 31, 2010, more than 10,000 physicians in more than 60 countries had ordered more than 190,000 Oncotype DX tests.

"Oncotype DX provides a fundamental change in our therapy policy, representing a step towards more personalized medicine in Europe," said Wolfgang Eiermann, Professor of Gynecology and Medical Director, Red Cross Women's Hospital Munich.  "Based on these data, there is a clear need for Oncotype DX to be included in daily clinical practice."

Oncotype DX Changes Physician Treatment Recommendations in Germany, Spain and the UK

  • Multiple Countries: In a meta-analysis of nine published decision impact studies with a total of 1,154 early-stage breast cancer patients, the RS result led to an approximately 35 percent change in treatment decisions.  The overall reduction of chemotherapy recommendations or use was approximately 24 percent.  The study, "Meta-analysis of the Decision Impact of the 21-Gene Breast Cancer Recurrence Score in Clinical Practice," will be presented on Thursday, March 17.
  • Germany: Results from 149 early-stage breast cancer patients with node negative disease and 48 patients with node positive disease in Germany showed that the use of the RS result can have an impact on adjuvant treatment decision making.  Specifically, based on the RS result, the adjuvant treatment recommendation changed in 38 percent of node negative cases and in 48 percent of node positive cases.  Knowledge of the RS result led to a change from chemotherapy plus hormonal therapy to hormonal therapy alone more commonly than from hormonal therapy alone to the addition of chemotherapy.  Overall, there was a 17 percent
    '/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
2. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
3. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
4. Researchers use genomics to investigate TB outbreak
5. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
6. Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue
7. Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
8. Four Community Hospitals Join DNA Directs Genomic Medicine Network
9. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
10. Everist Genomics Announces External Validation of OncoDefender™-CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
11. BioInformatics, LLC New Market Report - Genomics Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) today announced ... present an overview of the Company,s cancer,pipeline at ... Conference,in San Francisco. Dr. Henderson,s presentation will take ... Dr. Henderson,s presentation will be webcast live ...
... 17 BioMed Realty Trust, Inc.,(NYSE: BMR ) ... a,third quarter 2007 dividend of $0.31 per share of ... of $1.24 per common share. BioMed also announced ... $0.46094 per share of the company,s 7.375% Series A ...
... Surgery at the Forefront, SACRAMENTO, Calif., Sept. ... has formed a new company, Curexo Medical, Inc.,(CMI), ... Surgical Services,Inc. (ISS). Under the licensing agreement, Curexo, ... to CMI. Curexo Medical, Inc., located in ...
Cached Biology Technology:Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends 2New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product 2
(Date:7/21/2015)... YORK , July 21, 2015 ... systems, as seen in the recent U.S. Office ... a solution to the infosec conundrum, but developers ... is stored. To address this dilemma, Biometrics-as-a-Service provider ... its Biometric Tokenization SDK for third party integration. ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... This news release is available in French ... 2013 From office towers to shopping malls, educational institutions to ... all electricity consumed in Canada. Thanks to new research funding for ... and source of pollution. More than $2 million in funding ...
... in Florence last week. It provided us with some of the ... Did life begin on Mars rather than on earth?, Chelyabinsk meteor ... Bird", was probably a herbivore Goldschmidt2014 is due to ... so if you want to attend, put the dates in your ...
... planarian flatworms have the remarkable ability to regrow any missing ... study the molecular basis of regeneration. Over ... that differ depending on the severity of the injury they ... puncture wound reacts at the cellular and molecular levels quite ...
Cached Biology News:Buildings of the future 2Tissue loss triggers regeneration in planarian flatworms 2